

Limited Review Report

**The Board of Directors
TAKE Solutions Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results (the statement) of TAKE Solutions Limited for the quarter and half year ended September 30, 2020. This statement which is the responsibility of the Company's Management has been approved by the Board of Directors. The statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. We draw attention to the following matter in the Notes to the standalone financial results:

The management has taken into consideration the impact of the known internal and external events arising from COVID-19 pandemic in the assessment of recoverability of trade receivables, contract assets and certain investments in subsidiaries up to the date of approval of these financial results. In this assessment, the company has performed sensitivity analysis on the key assumptions used. Such review and analysis performed by the company did not reveal any impairment losses. However, the liquidity and business constraints consequent to impact of COVID 19 pandemic has significantly hampered the operations of a step-down subsidiary viz. Navitas Life Sciences GmbH, Germany (a subsidiary of Ecron Acunova Limited, which is a subsidiary of TAKE Solutions Limited) and the liquidation process has been initiated as per the requirements of local laws. While such liquidation proceedings are in progress, the loss of Rs. 15,662.33 lakhs to the extent of net assets has been accounted for in Consolidated Financial Statements in the previous quarter ended June 30, 2020. Considering the business projections, no impairment is required to be made against investments of the company in Ecron Acunova Limited in the Standalone Financial Results.



G. D. Apte & Co.
Chartered Accountants

Since the impact assessment of COVID-19 is an ongoing process given the uncertainties associated with its nature and duration, the Company will continue to closely monitor any significant impact on the financial position. The impact of global health pandemic might be different from that estimated as at the date of approval of these financial results.

Our conclusion is not modified in respect of the above matter.

For G. D. Apte & Co.
Chartered Accountants
Firm Registration Number: 100515W
UDIN: 20113053AAAADV4420




Umesh S. Abhyankar
Partner
Membership Number: 113 053
Pune, November 12, 2020





TAKE SOLUTIONS LTD
CIN: L63090TN2000PLC046338
Regd. Office : 27, Tank Bund Road, Nungambakkam, Chennai 600 034
www.takesolutions.com

Statement of Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2020

(₹ In Lakhs except per share data)

SL No.	Particulars	Quarter Ended			Half Year Ended	Year Ended
		Sep 30, 2020	Jun 30, 2020	Sep 30, 2019	Sep 30, 2020	Sep 30, 2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A	CONTINUING OPERATIONS					
1	Revenue from operations	166.57	1.73	91.28	168.30	139.74
2	Other Income	297.58	433.53	1,110.50	731.11	1,700.79
3	Total Income	464.15	435.26	1,201.78	899.41	1,840.53
4	Expenses					
	Cost of revenue	136.85	1.59	52.62	138.44	74.42
	Employee benefit expenses	104.94	122.93	166.37	227.87	352.37
	Finance cost	9.10	9.49	11.02	18.59	22.32
	Depreciation and amortisation	39.20	39.24	45.02	78.44	90.54
	Other expenses	471.84	192.40	380.99	664.24	607.09
	Total Expenses	761.93	365.65	656.02	1,127.58	1,133.13
5	Profit/(Loss) before tax (3-4)	(297.78)	69.61	545.76	(228.17)	2,160.49
6	Tax expense					
	Current tax	(12.34)	12.34	7.10	-	29.78
	Shortfall / (excess) provision of earlier years	-	-	-	-	(86.63)
	Deferred tax	7.03	(41.96)	(70.06)	(34.93)	(102.90)
7	Profit/(Loss) for the period from continuing operations (5-6)	(292.47)	99.23	608.72	(193.24)	2,493.82
B	DISCONTINUED OPERATIONS					
8	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-
9	Less: Tax expense on discontinued operations	-	-	-	-	-
10	Profit/(Loss) for the period from discontinued operations (8-9) after tax	-	-	-	-	-
11	Profit/(Loss) for the period (7+10)	(292.47)	99.23	608.72	(193.24)	2,493.82
12	Other Comprehensive Income					
a)	i) Items that will not be reclassified to profit or (loss)	9.75	(0.92)	(0.90)	8.83	(1.98)
	ii) Income tax provision / (reversal) relating to the items that will not be reclassified to profit or (loss)	2.45	(0.23)	(0.26)	2.22	(0.57)
b)	i) Items that will be reclassified to profit or (loss)	-	-	-	-	-
	ii) Income tax provision/(reversal) relating to the items that will be reclassified to profit or (loss)	-	-	-	-	-
13	Total Other Comprehensive Income	7.30	(0.69)	(0.64)	6.61	(1.41)
14	Total Comprehensive Income	(285.17)	98.54	608.08	(186.63)	765.50
15	Paid-up equity share capital (Face value ₹ 1/- each)	1,479.34	1,479.34	1,479.34	1,479.34	2,492.85
	Earnings per share (of ₹ 1/- each) (not annualised)					
	(a) Basic (in ₹)	(0.20)	0.07	0.41	(0.13)	0.52
	(b) Diluted (in ₹)	(0.20)	0.07	0.41	(0.13)	0.52
						1.69
						1.68



Note:

1. Standalone Statement of Assets and Liabilities

Particulars		(₹ In Lakhs)	
		As at Sep 30, 2020 (Unaudited)	As at Mar 31, 2020 (Audited)
ASSETS			
Non-current assets			
(a) Property, plant and equipment		195.81	232.11
(b) Right-of-use assets		323.00	365.13
(c) Other intangible assets		-	-
(d) Investment in subsidiaries		51,635.60	51,731.87
(e) Financial Assets			
(i) Loans		596.76	595.28
(ii) Other financial asset		-	-
(f) Deferred tax assets (net)		245.18	212.47
(g) Income tax assets (net)		821.48	814.37
(h) Other non-current assets		-	-
Total Non-Current Assets		53,817.83	53,951.23
Current assets			
(a) Inventories		11.24	2.45
(b) Financial assets			
(i) Investments		-	-
(ii) Trade receivables		1,011.82	1,246.80
(iii) Cash and cash equivalents		1,015.49	74.39
(iv) Bank balances other than (iii) above		27.33	29.35
(v) Loans		13,209.98	12,893.50
(vi) Other financial assets		9,491.65	10,572.88
(c) Other current assets		557.69	579.27
(d) Investment in subsidiary held for sale		358.19	-
Total Current Assets		25,683.39	25,398.64
Total Assets		79,501.22	79,349.87
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital		1,479.34	1,479.34
(b) Other equity		76,730.30	76,823.51
Total Equity		78,209.64	78,302.85
Non-current liabilities			
(a) Financial liabilities			
Other financial liabilities		192.94	216.65
(b) Lease liabilities		282.93	320.19
(c) Provisions		73.49	75.18
Total Non-Current Liabilities		549.36	612.02
Current liabilities			
(a) Financial liabilities			
(i) Trade Payables		162.53	94.89
(ii) Other financial liabilities		446.17	256.41
(b) Lease liabilities		70.31	64.51
(c) Other current liabilities		58.58	14.48
(d) Provisions		4.63	4.71
Total Current Liabilities		742.22	435.00
Total Equity and Liabilities		79,501.22	79,349.87



2. Standalone Statement of Cash flows

Particulars	(₹ In Lakhs)	
	Six months ended Sep 30, 2020 (Unaudited)	Six months ended Sep 30, 2019 (Unaudited)
A) CASH FLOW FROM OPERATING ACTIVITIES		
NET PROFIT/ (LOSS) BEFORE TAX	(228.17)	693.79
Adjustments for		
Depreciation	78.44	90.54
Finance Cost	18.59	22.32
Dividend income	-	(24.86)
Interest income	(402.39)	(469.85)
Unwinding of liability for financial guarantee contracts	(121.06)	-
Provision for gratuity, compensated absences & other benefits	8.69	5.26
Employee stock option expense	12.76	71.12
Bad debts and provision for expected credit losses	56.60	15.59
Foreign exchange adjustments - loss/(gain)	191.75	69.29
Lease concessions received	(50.05)	-
Operating Profit before working Capital Changes	(434.84)	473.20
(Increase)/Decrease in loans & advances and other assets	1,079.15	(483.10)
Increase/ (Decrease) in liabilities and provisions	218.00	(516.11)
Cash flow from/ (used in) Operations	862.31	(526.01)
Direct taxes paid	(7.11)	(55.83)
NET CASH FROM/(USED IN) OPERATING ACTIVITIES	855.20	(581.84)
B) CASH FLOW FROM INVESTING ACTIVITIES		
Dividend income	-	24.86
Interest income	-	469.85
Loans to related parties	85.90	(773.91)
Reduction/ (Increase) of bank deposits	-	2,545.50
NET CASH FROM /(USED IN) INVESTING ACTIVITIES	85.90	2,266.30
C) CASH FLOW FROM FINANCING ACTIVITIES		
Payment of lease liabilities	-	(60.46)
Dividends paid on equity share including dividend distribution tax	-	(708.30)
NET CASH FROM/(USED IN) FINANCING ACTIVITIES	-	(768.76)
Net Increase/(Decrease) in Cash & Cash equivalents	941.10	915.70
Add: Cash and Cash equivalents as at the beginning of the period	74.39	212.18
Cash & Cash equivalents as at the end of the period	1,015.49	1,127.88

Components of Cash and Cash equivalents	Sep 30 ,2020 (Unaudited)	Sep 30 ,2019 (Unaudited)
Balance with banks		
On current accounts	1,013.56	1,011.47
Deposit having original maturity less than 3 months	-	113.70
Cash on hand	1.93	2.71
Total	1,015.49	1,127.88

Notes

The above cash- flow statement has been prepared under the indirect method set out in Indian Accounting

- 1) Standard (IND AS) -7, 'Statement of Cash Flow' as specified in the Companies (Indian Accounting Standards) Rules, 2015.
- 2) Direct Taxes paid is treated as arising from operating activities and are not bifurcated between investment and financing activities.
- 3) All figures in brackets indicate cash outflow.




- 3 The Standalone Financial Results for the quarter and half year ended September 30, 2020 have been reviewed and recommended by the Audit Committee at its meeting held on November 11, 2020 and approved by the Board of Directors of the company at its meetings held on November 12, 2020. The Statutory Auditors of the company have carried out Limited Review of the results for the quarter and half year ended September 30, 2020.
- 4 The management has taken into consideration the impact of the known internal and external events arising from COVID-19 pandemic in the assessment of recoverability of trade receivables, contract assets and certain investments in subsidiaries up to the date of approval of these financial results. In this assessment, the company has performed sensitivity analysis on the key assumptions used. Such review and analysis performed by the company did not reveal any impairment losses. However, the liquidity and business constraints consequent to impact of COVID 19 pandemic has significantly hampered the operations of a step-down subsidiary viz. Navitas Life Sciences GmbH, Germany (a subsidiary of Ecron Acunova Limited, which is a subsidiary of TAKE Solutions Limited) and the liquidation process has been initiated as per the requirements of local laws. While such liquidation proceedings are in progress, the loss of Rs. 15,662.33 lakhs to the extent of net assets has been accounted for in Consolidated Financial Statements in the previous quarter ended June 30, 2020. Considering the business projections, no impairment is required to be made against investments of the company in Ecron Acunova Limited in the Standalone Financial Results.
- Since the impact assessment of COVID-19 is an ongoing process given the uncertainties associated with its nature and duration, the Company will continue to closely monitor any significant impact on the financial position. The impact of global health pandemic might be different from that estimated as at the date of approval of these financial results.
- 5 The Code on Social Security, 2020 (the Code) has been enacted, which would impact contribution by the Company towards applicable social security schemes. The effective date from which changes are applicable is yet to be notified and the rules thereunder are yet to be announced. The actual impact on account of this change will be evaluated and accounted for when notification becomes effective.
- 6 During the quarter, the company entered into an agreement to divest its entire equity stake in one of the subsidiary viz APA Engineering Pvt Ltd for a consideration of Rs 1,740 lakhs. Pending the transfer of shares, the investments of ₹ 358.19 lakhs have been disclosed as 'held for sale' as per Ind AS 105, "Non-current Assets Held for Sale and Discontinued Operations".
- 7 The company on a standalone basis operates in the business segment of promotion of services related to Life Sciences and hence there is only one business segment. The company on a standalone basis is primarily operating in India, which is considered as single geographical segment. Accordingly, segment information has not been separately disclosed.
- 8 During the quarter ended September 30, 2020, employees have not exercised any equity shares under Employee Stock Option Scheme of the Company.
- 9 Previous period figures have been regrouped /reclassified, wherever necessary to conform to current period's classification.

Place : Chennai
Date : November 12, 2020



For and on behalf of the Board of Directors


Srinivasan H.R.
Vice Chairman & Managing Director

